OncoMed Pharmaceuticals, Inc. (OMED) announced that it has commenced the third phase Ib study on pipeline candidate OMP-54F28 with Paraplatin and Taxol in patients with platinum-sensitive ovarian cancer.
We note that OncoMed is developing OMP-54F28 in collaboration with Bayer (BAYRY). OMP-54F28 targets the Wnt pathway. The primary endpoints of the study are to evaluate safety of this combination regimen and determine a recommended phase II dose for OMP-54F28 in combination with Paraplatin and Taxol. Secondary endpoints include evaluation of the pharmacokinetics (PK) and pharmacodynamics (PD) of OMP-54F28, as well as the efficacy of this combination.
The other two phase Ib studies on OMP-54F28, initiated earlier this year, are evaluating the candidate with Abraxane and Gemzar in pancreatic cancer and with Nexavar in hepatocellular cancer.
Another Wnt-pathway-targeting compound in the pipeline is OMP-18R5. In the last quarter of 2013, OncoMed started three phase Ib studies on OMP-18R5 in patients suffering from non-small cell lung cancer, Her2-negative breast cancer and stage IV pancreatic cancer.
Currently, all six of OncoMed's planned phase Ib studies for OMP-18R5 and OMP-54F28 are now in the process of enrolling patients. All six studies are being conducted under OncoMed’s collaboration with Bayer.
We believe investor focus will remain on updates pertaining to these studies. We are encouraged by the pipeline progress at OncoMed.
OncoMed currently carries a Zacks Rank #3 (Hold). Investors looking for better-ranked stocks in the biopharma sector may consider companies like Endocyte Inc. (ECYT) and Biogen Idec Inc. (BIIB). Both carry a Zacks Rank #1 (Strong Buy).
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment